세계 강직성 척추염 치료 시장 - 점유율 분석, 산업 동향, 통계 및 성장 예측(2024-2029년)

The Ankylosing Spondylitis Treatment Market size is estimated at USD 6.64 billion in 2024, and is expected to reach USD 9.72 billion by 2029, growing at a CAGR of 7.75% during the forecast period (2024-2029).

The COVID-19 pandemic impacted the ankylosing spondylitis market due to disruptions in various clinical studies and supply chains. COVID-19 was more common in people with ankylosing spondylitis who were taking immunosuppressive medications. For instance, an article published in BMC Journal in January 2023 stated that an electronic medical-record management system (EMRMS) was implemented at the Taichung Veterans General Hospital (TCVGH) for patients with ankylosing spondylitis (AS). The study found that the disease activity of AS worsened after the number of COVID-19 cases increased in Taiwan.

However, people with ankylosing spondylitis managed their care through telehealth visits that were carried out virtually, which compensated for the market growth in the later phase of the pandemic. The ankylosing spondylitis market started recovering since the restrictions were lifted. The market is gradually growing due to the rising product approvals and launches by market players. The market is expected to register a stable growth rate during the forecast period.

The growth of the ankylosing spondylitis treatment market is majorly driven by an increase in the prevalence rate of the target disease and rising reimbursements by government and private organizations for the treatment.

For instance, according to a StatPearls article updated in April 2022, ankylosing spondylitis (AS) is diagnosed in people younger than 40 years, and approximately 80% of patients develop first symptoms when they are younger than 30 years old. Therefore, the high burden of AS is expected to propel the AS treatment market during the forecast period.

Furthermore, the recent advancement in therapy, growing awareness about the treatments for the disease, and the development of effective drugs are the major contributors to the growth of the market. Additionally, government initiatives and advanced healthcare infrastructure are expected to propel market growth over the forecast period. For instance, in August 2022, the National Institute for Health and Care Excellence (NICE) approved reimbursement for AbbVie's Rinvoq (upadacitinib) in the United Kingdom. Such reimbursements to reduce the economic burden of a patient undergoing treatment are expected to propel market growth.

The rising clinical trials for the development of ankylosing treatment are expected to propel the demand for treatment. For instance, a phase II clinical trial was initiated in June 2021 to assess the efficacy and safety of subcutaneous SHR-1314 in patients with Active Ankylosing Spondylitis. The trial was sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and the expected completion is in March 2024. The high number of clinical trials indicates the high demand for ankylosing spondylitis treatment during the forecast period.

Additionally, the strategic initiatives by market players such as research and development to develop innovative treatments, rising approvals, and product launches are contributing to the growth of the market. For instance, in September 2023, the United States Food and Drug Administration (FDA) provided approval to the intravenous (IV) formulation of Cosentyx by Novartis for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Similarly, in February 2021, Affibody AB received the United States Food and Drug Administration (FDA) clearance to proceed with phase 2 trials of Izokibep (engineered protein), indicated for patients with ankylosing spondylitis, which is designed to have high potency and a long half-life. Therefore, the rising clinical trial developments to develop innovative treatment is expected to propel the market growth.

Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is expected to impede market growth.

Ankylosing Spondylitis Treatment Market Trends

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as a first-line drug treatment for Ankylosing Spondylitis (AS). The segment is expected to hold a significant market share owing to the high burden of AS, rising research and development leading to the development of innovative NSAIDs for the treatment. For instance, according to a Statpearls article updated in September 2022, Naproxen is FDA-approved for treating acute gout, ankylosing spondylitis, and other musculoskeletal diseases. According to various research studies, all NSAIDs were significantly more effective in reducing pain severity in AS patients. Therefore, the demand for NSAIDs is high which is expected to augment the segment growth during the forecast period.

Furthermore, the strategic initiatives that market players adopt, such as product launches, approvals, and partnerships, also contribute to the segments' growth. For instance, in April 2022, RINVOQ (upadacitinib) was approved by U.S. FDA as an oral treatment for adults with active ankylosing spondylitis, who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. RINVOQ delivered rapid and meaningful disease control across two pivotal trials.

Additionally, in December 2021, Pfizer received approval from the United States Food and Drug Administration (FDA) for tofacitinib, known as Xeljanz or Xeljanz XR, a new medication to treat ankylosing spondylitis (AS) and other disorders like rheumatoid arthritis, juvenile Idiopathic Arthritis. The approvals of innovative NSAIDs are expected to propel its demand and augment the segment's growth during the forecast period.

North America is Expected to Hold a Significant Market Share Over the Forecast Period

North America is expected to hold a significant market share owing to the high prevalence of target diseases, rising product approvals and launches by market players, and rising government and private organizations reimbursements.

According to an article published in Rheumatology Therapy Journal in December 2021, the prevalence of AS in the United States was 0.2% - 0.5%. The increasing trend of the prevalence of AS in the region is expected to boost the demand for treatment, thereby accelerating market growth.

Furthermore, rising research and development by market players to develop an efficient treatment for ankylosing spondylitis treatment leading to product approvals and launches are expected to propel the market growth. For instance, in December 2021, Coherus Biosciences received the United States Food and Drug Administration (FDA) approval for its Yusimry (adalimumab). It is a tumor necrosis factor (TNF) blocker biosimilar to Humira for treating AS. Also, in July 2022, AbbVie received Health Canada approval for RINVOQ (upadacitinib, 15 mg), an oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active ankylosing spondylitis (AS). The development and approval of advanced treatments are expected to propel market growth in the region.

In addition, various government and non-profit organizations provide reimbursements or patient assistance for reducing the economic burden of patients undergoing AS treatment. For instance, the Patient Access Network (PAN) Foundation is a US-based non-profit organization that provides USD 5,200 in assistance per year to Ankylosing Spondylitis patients.

Therefore, the North American region is expected to witness growth during the forecast period due to the aforesaid factors such as the high burden of disease, rising product approvals, and launches, and high reimbursements.

Ankylosing Spondylitis Treatment Industry Overview

The ankylosing spondylitis treatment market is moderately competitive with several players across the globe. The majority of the key player is involved in the research and manufacturing of ankylosing spondylitis therapy drugs. These market players have gained a high market share and offer a wide range of products with an extensive distribution system across the world. Some of the major key players are Novartis, Amgen, Boehringer Ingelheim International GmbH, UCB Biopharma, and AbbVie.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Burden of Target Diseases and Rising Reimbursements for the Treatment
  • 4.2.2 Research and Development for Effective Treatment
• 4.3 Market Restraints
  • 4.3.1 High Cost of Treatment
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD)

• 5.1 By Treatment Types
  • 5.1.1 Medication
    • 5.1.1.1 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.1.1.2 TNF Inhibitors
    • 5.1.1.3 IL-17 Inhibitors
    • 5.1.1.4 Others
  • 5.1.2 Therapy
  • 5.1.3 Surgery
• 5.2 Geography
  • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
  • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
  • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
  • 5.2.4 Middle East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East and Africa
  • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Novartis AG (Sandoz)
  • 6.1.2 AbbVie Inc.
  • 6.1.3 UCB
  • 6.1.4 Amgen Inc.
  • 6.1.5 Boehringer Ingelheim International GmbH
  • 6.1.6 Celltrion Healthcare
  • 6.1.7 Reliance Life Sciences
  • 6.1.8 Johnson & Johnson Services, Inc.
  • 6.1.9 Eli Lilly and Company
  • 6.1.10 Gilead Sciences, Inc.
  • 6.1.11 Merck & Co., Inc.
  • 6.1.12 Pfizer Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS